Relapsing Multiple Sclerosis (RMS) Latest Advances
Find the Latest Research About Relapsing Multiple Sclerosis (RMS)
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11540 publications
Corrigendum to "Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study" [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885].
Journal: Multiple sclerosis and related disorders
Published: April 10, 2026
Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.
Journal: Neurology
Published: April 09, 2026
A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study.
Journal: Neurodegenerative disease management
Published: April 07, 2026
Cytomegalovirus Drives the Development of Cytotoxic CD4+ T Cells in Patients With Multiple Sclerosis.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: March 23, 2026
De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: March 19, 2026
Resting-State EEG Microstates as Dynamic Biomarkers of Network Dysfunction and Cognitive Impairment in Patients With Multiple Sclerosis.
Journal: Neurology
Published: March 19, 2026
Evaluation of cognitive impairments in multiple sclerosis: a comparative analysis of the Rey complex figure test and the symbol digit modalities test.
Journal: Arquivos de neuro-psiquiatria
Published: March 11, 2026
Threshold-Dependent Discordance Between STRATIFY JCV™ and IMMUNOWELL™ Assays in Relapsing Multiple Sclerosis.
Journal: Neurology and therapy
Published: February 23, 2026
Tolebrutinib Phase 2b Long-Term Extension Study: Two-Year Safety, MRI, and Clinical Efficacy Outcomes in Patients With Relapsing Multiple Sclerosis Patients.
Journal: Neurology open access
Published: February 20, 2026
High burden of poor prognostic factors at first presentation in treatment-naïve relapsing multiple sclerosis: Real-world evidence from a large Egyptian cohort.
Journal: Multiple sclerosis and related disorders
Published: February 18, 2026
GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: February 18, 2026
Last Updated: 04/28/2026